Abstract: The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.
Type:
Grant
Filed:
September 5, 2014
Date of Patent:
January 10, 2017
Assignee:
MALLINCKRODT LLC
Inventors:
Krishna Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
Type:
Grant
Filed:
June 26, 2014
Date of Patent:
December 27, 2016
Assignee:
Mallinckrodt LLC
Inventors:
Gary L. Cantrell, Raghavan Rajagopalan, Amolkumar Karwa, Richard B. Dorshow
Abstract: A solid composition comprises: MnO2; and a compound represented by the general formula (I) wherein: R is a polymer; each Y is independently a hydrogen or a negative charge; Z is either hydrogen or is not present; each n is independently 1, 2, 3, 4, 5 or 6; wherein the MnO2 is bound to the compound of formula (I) so as to coat the surface thereof. Such a composition may be used for the separation of polyvalent metal species, such as Mo, from one or more accompanying impurities.
Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
Type:
Grant
Filed:
June 26, 2014
Date of Patent:
December 13, 2016
Assignee:
Mallinckrodt LLC
Inventors:
Gary L. Cantrell, Raghavan Rajagopalan, Amolkumar Karwa, Richard B. Dorshow
Abstract: Described herein are methods of preparing 6-hydroxy N-alkyl morphinan-6-ols from morphinan-6-ones, as illustrated below: wherein the variables R1, R2, R3, R10, R11, R14, and are as defined herein and wherein the reactions occur in a one-pot procedure using a boron based reducing agent.
Abstract: The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% of 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.
Abstract: The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.
Type:
Grant
Filed:
February 20, 2015
Date of Patent:
October 18, 2016
Assignee:
MALLINCKRODT LLC
Inventors:
Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
Abstract: The present invention provides processes for the synthesis of substituted berbine compounds. Also provided are intermediates used in the synthesis of substituted berbine compounds.
Type:
Grant
Filed:
September 2, 2009
Date of Patent:
October 4, 2016
Assignee:
Mallinckrodt LLC
Inventors:
Peter X. Wang, Frank W. Moser, Gary L. Cantrell, Christopher W. Grote
Abstract: The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that include one or more photoactive moieties. The present invention further includes imaging and therapeutic methods using one or more optical agents of the present invention including optically functional shell cross-linked micelles having an associated therapeutic agent.
Type:
Application
Filed:
February 26, 2016
Publication date:
September 8, 2016
Applicants:
Mallinckrodt LLC, Washington University, The Texas A&M University System
Inventors:
William L. Neumann, Richard B. Dorshow, John N. Freskos, Karen L. Wooley, Nam S. Lee, Yun Lin, Guorong Sun
Abstract: The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.
Type:
Grant
Filed:
June 11, 2014
Date of Patent:
September 6, 2016
Assignee:
MALLINCKRODT LLC
Inventors:
Krishna R. Devarakonda, Michael J. Giuliani, Vishal K. Gupta, Ralph A. Heasley, Susan Shelby
Abstract: An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.
Type:
Grant
Filed:
December 12, 2014
Date of Patent:
August 16, 2016
Assignee:
Mallinckrodt LLC
Inventors:
Peter X. Wang, Robert E. Halvachs, Kevin R. Roesch, Henry J. Buehler, Joseph P. Haar, Jr., Gary L. Cantrell
Abstract: Various embodiments of pharmaceutical product containers are disclosed. Each pharmaceutical product container includes a cap, a container body, and a locking mechanism. The locking mechanism is disposable from a locked state to an unlocked state at least when the cap is in a closed position relative to the container body (e.g., to define an enclosed space for pharmaceutical product). Once in the locked state and with the cap being in a closed position, the locking mechanism is unable to return to its unlocked state. Pharmaceutical product enclosed within the container with the locking mechanism being in its locked state may then be disposed of in any appropriate manner (e.g., discarded in the trash).
Abstract: The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.
Type:
Grant
Filed:
October 31, 2012
Date of Patent:
June 21, 2016
Assignee:
MALLINCKRODT LLC
Inventors:
Jun Yang, Stephen H. Wu, Cliff J. Herman
Abstract: The invention generally provides processes for the preparation of radioiodinated 3-fluoropropyl-nor-?-CIT. In particular, the process uses an arylsilane intermediate, thus avoiding the use of hexamethylditin, and reducing the number of steps previously required for the preparation of radioiodinated 3-fluoropropyl-nor-?-CIT from anhydroecgonine methyl ester. The invention also relates to the alkylation of a nortropane to the corresponding N-(3-fluoropropyl) analog using 3-fluoropropanal.
Abstract: The present disclosure provides an immediate release, abuse deterrent pharmaceutical solid dosage form comprising at least one functional score. In particular, the immediate release, abuse deterrent solid dosage form comprises at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
April 5, 2016
Assignee:
MALLINCKRODT LLC
Inventors:
Siva N. Raman, Jae Han Park, Sunil K. Battu, Eric A. Burge, David W. Bogan
Abstract: The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that include one or more photoactive moieties. The present invention further includes imaging and therapeutic methods using one or more optical agents of the present invention including optically functional shell cross-linked micelles having an associated therapeutic agent.
Type:
Grant
Filed:
November 17, 2011
Date of Patent:
March 29, 2016
Assignees:
Mallinckrodt LLC, The Texas A&M University System, Washington University
Inventors:
William L. Neumann, Richard B. Dorshow, John N. Freskos, Karen L. Wooley, Nam S. Lee, Yun Lin, Guorong Sun
Abstract: The present invention provides compositions of 6-amino morphinan compounds and process for their synthesis. In particular, the processes provide for the reductive amination of 6-keto morphinans by catalytic transfer hydrogenation, to produce 6-amino morphinan compounds, which are epimerically and/or diastereomerically enriched.
Type:
Grant
Filed:
June 8, 2012
Date of Patent:
March 29, 2016
Assignee:
MALLINCKRODT LLC
Inventors:
Christopher W. Grote, Joseph P. McClurg, John E. Johnson, Jr., Sarah M. Farris
Abstract: A system for assaying an eluate for Technetium-99m and Molybdenum-99 content includes an inner ionization chamber including a well configured to receive the eluate, an outer ionization chamber concentric with the inner ionization chamber, and attenuating material positioned between the inner and outer ionization chambers. A computing device is configured to determine a Technetium-99m content of the eluate based on a first current measured in the inner ionization chamber, and determine a Molybdenum-99 content of the eluate based on at least a second current measured in the outer ionization chamber.
Type:
Grant
Filed:
October 27, 2014
Date of Patent:
March 15, 2016
Assignee:
MALLINCKRODT LLC
Inventors:
Kevin B. Graves, Bryan S. Petrofsky, Sumit Verma
Abstract: A process of treating hydrogen gas liberated from the acid or alkaline dissolution of a metal is provided. The process comprises a step of passing the liberated hydrogen gas through a reactor containing an oxidizing agent for oxidation of the hydrogen gas into water, followed by a step of regenerating the oxidizing agent. Also provided is an apparatus for carrying out the process, the apparatus comprising a reactor containing the oxidizing agent, wherein the reactor is at least partially immersed in an alumina bath.
Abstract: A compound comprising a metal chelate linked to a hexose carrier for use as a metallopharmaceutical diagnostic or therapeutic agent is provided. The compound is suitable for imaging by single-photon emission computed tomography, computer assisted tomography, magnetic resonance spectroscopy, magnetic resonance imaging, positron emission tomography, fluorescence imaging or x-ray.